Evidential Estimation of an Uncertain Mixed Exponential Distribution under Progressive Censoring.

Entropy (Basel)

School of Mathematics and Statistics, Northwestern Polytechnical University, Xi'an 710072, Shaanxi, China.

Published: September 2020

In this paper, the evidential estimation method for the parameters of the mixed exponential distribution is considered when a sample is obtained from Type-II progressively censored data. Different from the traditional statistical inference methods for censored data from mixture models, here we consider a very general form where there is some uncertain information about the sub-class labels of units. The partially specified label information, as well as the censored data are represented in a united frame by mass functions within the theory of belief functions. Following that, the evidential likelihood function is derived based on the completely observed failures and the uncertain information included in the data. Then, the optimization method using the evidential expectation maximization algorithm (E2M) is introduced. A general form of the maximal likelihood estimates (MLEs) in the sense of the evidential likelihood, named maximal evidential likelihood estimates (MELEs), can be obtained. Finally, some Monte Carlo simulations are conducted. The results show that the proposed estimation method can incorporate more information than traditional EM algorithms, and this confirms the interest in using uncertain labels for the censored data from finite mixture models.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597217PMC
http://dx.doi.org/10.3390/e22101106DOI Listing

Publication Analysis

Top Keywords

censored data
16
evidential likelihood
12
evidential estimation
8
mixed exponential
8
exponential distribution
8
estimation method
8
mixture models
8
general form
8
likelihood estimates
8
evidential
6

Similar Publications

Numerous studies have solved the problem of monitoring statistical processes with complete samples. However, censored or incomplete samples are commonly encountered due to constraints such as time and cost. Adaptive progressive Type II hybrid censoring is a novel method with the advantages of saving time and improving efficiency.

View Article and Find Full Text PDF

Assessing Cigarette Reduction Tax-Effectiveness in Low Tobacco Expenditure Contexts: An Application to Bolivia.

Health Econ

January 2025

Centro de Investigaciones Económicas y Empresariales, Universidad Privada Boliviana, La Paz, Bolivia.

In this research we show that ambitious increases in tobacco tax rates can substantially reduce tobacco consumption, increase fiscal revenue, and provide net positive social benefits even in contexts of low consumption prevalence and intensity. Low nicotine intake still constitutes a grave disease risk factor, and the effectiveness of tax increases might be questioned if income effects are small. We adapt spatial variation of price methodologies to deal with low prevalence and intensity, censored data, and small samples using the Bolivian case as an illustration.

View Article and Find Full Text PDF

Determining timeframes to death for imminently dying patients: a retrospective cohort study.

BMC Palliat Care

January 2025

Caring Futures Institute, Flinders University, Sturt Rd, Bedford Park, Adelaide, South Australia, 5042, Australia.

Background: Clinicians are frequently asked 'how long' questions at end-of-life by patients and those important to them, yet predicting timeframes to death remains uncertain, even in the last weeks and days of life. Patients and families wish to know so they can ask questions, plan, make decisions, have time to visit and say their goodbyes, and have holistic care needs met. Consequently, this necessitates a more accurate assessment of empirical data to better inform prognostication and reduce uncertainty around time until death.

View Article and Find Full Text PDF

Comparison of Oncology Drug Lag in Japan and South Korea Based on the Interval between the U.S. Approval and the Local Approval.

Biol Pharm Bull

January 2025

Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.

Drug lag is a serious issue for patients with life-threatening diseases such as cancer. Japan and Korea have been facing a large drug lag, despite having a large market and a good clinical trial environment. We analyzed drug lags for anticancer drugs between these countries, using the information on 82 anticancer drugs approved in the United States between 2017 and 2022.

View Article and Find Full Text PDF

Impact of pulmonary rehabilitation on survival in people with Interstitial lung disease.

Chest

January 2025

Respiratory Research@Alfred, Central Clinical School, Monash University, VIC, Australia; Institute for Breathing and Sleep, VIC, Australia; Department of Physiotherapy, Alfred Health, VIC, Australia.

Background: Pulmonary rehabilitation (PR) is a beneficial intervention for people with interstitial lung disease (ILD), however the effect of PR on survival is unclear. This study compared the survival outcomes in people with ILD who were allocated to PR versus those who were allocated to control in two published randomised controlled trials (RCTs).

Research Question: Does participation in PR impact survival among people with ILD?

Study Design And Methods: The combined data from the two previous RCTs of PR in ILD were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!